62-Month follow-up of ABCSG-12: Adjuvant endocrine therapy, alone or in combination with zoledronic acid, in premenopausal patients with endocrine-responsive early breast cancer

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Poestlberger, S; Steger, G; Jakesz, R; Singer, C; Eidtmann, H; Greil, R BONE. 2011; 48(1): S17-S17.

Transient elastography (FibroScan) for the prediction of liver toxicity following autologous or allogeneic HSCT

Nachbaur, D; Auberger, J; Graziadei, I; Vogel, W; Clausen, J ONKOLOGIE. 2011; 34: 277-277.

Open-Label, Prospective, Multicentre, Phase I/II Study of AOP2014, a Novel PEG-Proline-Interferon Alpha-2b in Patients with Polycythemia Vera: Update from an Ongoing Study

Gisslinger, H; Kralovics, R; Schoder, R; Gisslinger, B; Buxhofer-Ausch, V; Strecker, K; Wolf, D; Willenbacher, E; Greil, R; Egle, A; Melchardt, T; Burgstaller, S; Tarmann, FJ; Wachter, C; Zahriycick, O; Thaler, J BLOOD. 2011; 118(21): 762-762.

Activity of Azacitidine in 26 Unselected, Consecutive CMML Patients Included in the Austrian Azacitidine Registry (AAR) of the AGMT-Study Group

Pleyer, L; Stauder, R; Burgstaller, S; Schreder, M; Tinchon, C; Pfeilstocker, M; Steinkirchner, S; Melchardt, T; Mitrovic, M; Girschikofsky, M; Lang, A; Krippl, P; Egle, A; Sliwa, T; Linkesch, W; Fridrik, MA; Greil, R BLOOD. 2011; 118(21): 747-747.

CD44-hyaluronan interactions in the pathophysiology of chronic lymphocytic leukemia – regulation by cell activation

Girbl, T; Asslaber, D; Brachtl, G; Denk, U; Weiss, L; Naor, D; Greil, R; Hartmann, TN ONKOLOGIE. 2011; 34: 140-140.

The oncogenic miR-17-92 cluster and miR-155 define ALK status in anaplastic large cell lymphoma

Griessl, R; Hamacher, F; Sifft, E; Scheideler, M; Kenner, L; Greil, R; Merkel, O ONKOLOGIE. 2011; 34: 135-135.

Bone marrow may be the preferable graft source for transplant recipients homozygous for HLA-C group 2 ligands for inhibitory killer Ig-like receptors

Clausen, J; Kircher, B; Schumacher, P; Grabmer, C; Muhlbacher, A; Gastl, G; Nachbaur, D BONE MARROW TRANSPL. 2011; 46: S121-S121.

DOSE-ESCALATION WITH BEACOPP ESCALATED IS SUPERIOR TO ABVD IN THE COMBINED-MODALITY TREATMENT OF EARLY UNFAVORABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL

Borchmann, P; Diehl, V; Plutschow, A; Von Tresckow, B; Markova, J; Hitz, F; Kra, Z; Greil, R; Topp, MS; Villalobos, M; Zijlstra, JM; Sokler, M; Fuchs, M; Engert, A ANN ONCOL. 2011; 22: 180-180.

Breakthrough fungal infections (bIFI), fungal colonization and emergence of resistant strains during posaconazole (PCZ) prophylaxis in patients at risk. Real-life data from a single center institutional retrospective observational study

Auberger, J; Clausen, J; Mrazek, C; Lass-Florl, C; Nachbaur, D ONKOLOGIE. 2011; 34: 232-232.

A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results

Egle, A; Steurer, M; Gassner, F; Geisberger, R; Melchardt, T; Weiss, L; Fridrik, MA; Thaler, J; Lang, A; Greil, R BLOOD. 2011; 118(21): 135-136.